Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer

There is an urgent need for qualified predictive biomarkers of sensitivity for the treatments used in patients with castration-resistant prostate cancer (CRPC). We attempted to identify ready-to-use clinical predictors of improved outcome in metastatic CRPC (mCRPC) patients treated with next generation androgen receptor (AR) axis targeted drugs.

We reviewed a cohort of patients who received AR axis targeted drugs for CRPC at two major French cancer centres The predictive role of several clinical, biological and radiological parameters on progression-free survival (PFS) was studied

The study cohort consisted of 173 patients Median duration of response to initial androgen deprivation therapy (ADT) (time to castration resistance, TTCRPC) was 17 8months The 50% prostate-specific antigen (PSA) response rate to AR axis targeted drugs was 16% (95% confidence interval (CI): 6-27) and 41% (95% CI: 30-47) in patients with TTCRPC of under and over 12months respectively (p=0 005) Median PFS was 2 8months (95% CI: 2 1-3 9) and 5 8 (95% CI: 4 6-7 8; HR: 0 58, p=0 002) In patients treated with post-docetaxel enzalutamide (n=57), median PFS was 2 8months and 8 6months, (Hazard ratio (HR)=3 1; 95% CI: 1 6-5 8, p=0 0016) according to TTCRPC, whereas no difference was observed in placebo-treated patients (n=27) The 50% PSA response rate to enzalutamide was 8% (95% CI: 0-38) and 58% (95% CI: 42-73) in patients with a TTCRPC of under and over 12months respectively (p

The previous duration of response to ADT is a predictor of sensitivity to next generation AR axis targeted drugs in patients with mCRPC

European journal of cancer (Oxford, England : 1990) 2015 Jul 21 [Epub ahead of print]

Yohann Loriot, Jean-Christophe Eymard, Anna Patrikidou, Ecaterina Ileana, Christophe Massard, Laurence Albiges, Mario Di Palma, Bernard Escudier, Karim Fizazi

Department of Cancer Medicine, Gustave Roussy Institute, Cancer Campus, Grand Paris, University of Paris-Sud, Villejuif, France Electronic address: yohann loriot@gustaveroussy fr , Institut Jean Godinot, Reims, France , Department of Cancer Medicine, Gustave Roussy Institute, Cancer Campus, Grand Paris, University of Paris-Sud, Villejuif, France , Department of Cancer Medicine, Gustave Roussy Institute, Cancer Campus, Grand Paris, University of Paris-Sud, Villejuif, France , Department of Cancer Medicine, Gustave Roussy Institute, Cancer Campus, Grand Paris, University of Paris-Sud, Villejuif, France , Department of Cancer Medicine, Gustave Roussy Institute, Cancer Campus, Grand Paris, University of Paris-Sud, Villejuif, France , Department of Cancer Medicine, Gustave Roussy Institute, Cancer Campus, Grand Paris, University of Paris-Sud, Villejuif, France , Department of Cancer Medicine, Gustave Roussy Institute, Cancer Campus, Grand Paris, University of Paris-Sud, Villejuif, France , Department of Cancer Medicine, Gustave Roussy Institute, Cancer Campus, Grand Paris, University of Paris-Sud, Villejuif, France

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe